Longeveron Inc.

LGVN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $1.2M $2.4M $709.0K $1.2M $1.3M $5.6M
Cost of Revenue $396.0K $508.0K $488.0K $725.0K $716.0K $3.8M
Gross Profit $803.0K $1.9M $221.0K $497.0K $590.0K $1.8M
Gross Margin 67.0% 78.8% 31.2% 40.7% 45.2% 32.4%
Operating Expenses
Research & Development $12.0M $8.1M $9.1M $9.4M $7.1M $2.7M
SG&A Expense $12.0M $10.3M $12.2M $8.1M $9.7M $2.7M
Operating Income $-23.3M $-16.5M $-21.0M $-18.0M $-17.5M $-3.8M
Operating Margin -1,942.2% -690.7% -2,966.0% -1,476.5% -1,336.6% -67.1%
Interest Expense — — — $1.4M $4.0K $7.0K
Pretax Income — — — — — —
Income Tax Expense $0 $0 $0 $0 — —
Net Income $-22.7M $-16.0M $-21.4M $-18.8M $-17.0M $-3.7M
Net Margin -1,893.6% -667.8% -3,020.2% -1,541.3% -1,305.1% -66.1%
EPS (Basic) $-1.29 $-2.62 $-2.56 $0.00 $0.00 $0.00
EPS (Diluted) $-1.29 $-2.62 $-2.56 $0.00 $0.00 $0.00
Shares Outstanding (Basic) 17.58B 9.41B 8.69B 8.72B 7.87B —
Shares Outstanding (Diluted) 17.58B 9.41B 8.69B 8.72B 7.87B —
Dividends Per Share — — — — — —